Your browser doesn't support javascript.
loading
Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis.
Damart, Julien; Filippou, Georgios; Andrès, Mariano; Cipolletta, Edoardo; Sirotti, Silvia; Carboni, Davide; Filippucci, Emilio; Diez, Pilar; Abhishek, Abhishek; Latourte, Augustin; Ea, Hang-Korng; Ottaviani, Sébastien; Letarouilly, Jean-Guillaume; Desbarbieux, Renaud; Graf, Sahara; Norberciak, Laurène; Richette, Pascal; Pascart, Tristan.
Afiliación
  • Damart J; Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France.
  • Filippou G; Department of Rheumatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
  • Andrès M; Department of Rheumatology, Dr Balmis General University Hospital-ISABIAL, Miguel Hernandez University, Alicante, Spain.
  • Cipolletta E; Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Sirotti S; Department of Rheumatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
  • Carboni D; Department of Rheumatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
  • Filippucci E; Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Diez P; Department of Rheumatology, Dr Balmis General University Hospital-ISABIAL, Miguel Hernandez University, Alicante, Spain.
  • Abhishek A; Academic Rheumatology, University of Nottingham, Nottingham, UK.
  • Latourte A; Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, 2 rue Ambroise Paré, Paris, France; Bioscar UMR Inserm 1132 and Université de Paris Cité, Paris, France.
  • Ea HK; Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, 2 rue Ambroise Paré, Paris, France; Bioscar UMR Inserm 1132 and Université de Paris Cité, Paris, France.
  • Ottaviani S; Department of Rheumatology, Hôpital Bichat APHP Paris Nord and Université de Paris, Paris, France.
  • Letarouilly JG; Université de Lille, Centre Hospitalier Universitaire Lille, MABLab ULR 4490, Service de Rhumatologie, Lille, France.
  • Desbarbieux R; Department of Rheumatology, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
  • Graf S; Department of Biostatistics and Methodology, Saint-Philibert Hospital, Lille Catholic University, Lille, France.
  • Norberciak L; Department of Biostatistics and Methodology, Saint-Philibert Hospital, Lille Catholic University, Lille, France.
  • Richette P; Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, 2 rue Ambroise Paré, Paris, France; Bioscar UMR Inserm 1132 and Université de Paris Cité, Paris, France.
  • Pascart T; Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France.
Rheumatology (Oxford) ; 63(2): 446-455, 2024 Feb 01.
Article en En | MEDLINE | ID: mdl-37216917
OBJECTIVES: Very little is known on the efficacy and safety of drugs for the management of chronic calcium pyrophosphate (CPP) crystal inflammatory arthritis. The objectives of this work were to describe the drugs used in the management of chronic CPP crystal inflammatory arthritis in expert European centres, and to examine treatment retention. METHODS: This was a retrospective cohort study. Charts from patients with a diagnosis of persistent inflammatory and/or recurrent acute CPP crystal arthritis were reviewed in seven European centres. Baseline characteristics were collected, and visits at months 3, 6, 12 and 24 included an assessment of treatment response and safety. RESULTS: One hundred and ninety-four treatments were initiated in 129 patients. Colchicine (used first-line in n = 73/86), methotrexate (used first-line in n = 14/36), anakinra (n = 27) and tocilizumab (n = 25) were the most prescribed treatments, while long-term corticosteroids, hydroxychloroquine, canakinumab and sarilumab were used occasionally. The 24-month on-drug retention was higher for tocilizumab (40%) than anakinra (18.5%) (P < 0.05), while the difference between colchicine (29.1%) and methotrexate (44.4%) was not statistically significant (P = 0.10). Adverse events led to 14.1% of colchicine discontinuations (100% of diarrhoea), 4.3% for methotrexate, 31.8% for anakinra and 20% for tocilizumab; all other discontinuations were related to insufficient response or losses to follow-up. Efficacy outcomes did not differ significantly between treatments throughout follow-up. CONCLUSION: Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis / Productos Biológicos / Antirreumáticos Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis / Productos Biológicos / Antirreumáticos Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia